Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimeric-001 followed by TIV for Influenza
NCT02293317Phase 2Completed
- Sponsor
- Scinai Immunotherapeutics Ltd.
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of multimeric-001 in influenza, sponsored by Scinai Immunotherapeutics Ltd.. Started Nov 2014; status: completed.
02
Drugs
multimeric-001
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02293317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293317.